New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
10:08 EDTSNV, NFLX, EXPE, EZCH, AWI, WHZ, SNDK, MDT, EXC, DSW, AINV, LUV, PEG, LAZ, EGN, XEC, AEM, WMBOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Agnico-Eagle (AEM) upgraded at BMO Capital... Apollo Investment (AINV) upgraded to Outperform from Market Perform at Keefe Bruyette... Armstrong World (AWI) upgraded to Conviction Buy from Buy at Goldman... Cimarex Energy (XEC) upgraded to Buy from Neutral at Global Hunter... DSW (DSW) upgraded to Buy from Neutral at Goldman... EZchip (EZCH) upgraded to Strong Buy from Buy at Feltl... Energen (EGN) upgraded to Accumulate from Neutral at Global Hunter... Exelon (EXC) upgraded to Buy from Hold at Jefferies... Expedia (EXPE) upgraded to Positive from Neutral at Susquehanna... Lazard (LAZ) upgraded to Buy from Neutral at UBS... Medtronic (MDT) upgraded at Credit Suisse... Netflix (NFLX) upgraded to Overweight from Equal Weight at Morgan Stanley... PSEG (PEG) upgraded to Buy from Hold at Jefferies... SanDisk (SNDK) upgraded to Outperform from Underperform at CLSA... Southwest (LUV) upgraded at Stifel... Synovus (SNV) upgraded to Buy from Hold at Drexel Hamilton... Whiting USA Trust (WHZ) upgraded at RW Baird... Williams (WMB) upgraded to Buy from Hold at Deutsche Bank.
News For AEM;AINV;AWI;XEC;DSW;EZCH;EGN;EXC;EXPE;LAZ;MDT;NFLX;PEG;SNDK;SNV;LUV;WHZ;WMB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
March 17, 2015
07:01 EDTDSWDSW reports Q4 adjusted EPS 35c, consensus 28c
Subscribe for More Information
05:53 EDTSNDKStocks with implied volatility movement; WLL SNDK
Stocks with implied volatility movement; Whiting Petroleum (WLL) 86, SanDisk (SNDK) 36 according to iVolatility.
05:50 EDTNFLXStocks with implied volatility movement; DD NFLX
Subscribe for More Information
March 16, 2015
16:28 EDTNFLXOn The Fly: Closing Wrap
Subscribe for More Information
15:26 EDTDSWNotable companies reporting before tomorrow's open
Subscribe for More Information
13:33 EDTLUVSouthwest price target raised to $56 from $46 at Argus
Subscribe for More Information
13:16 EDTMDTAnalysts upbeat on results of Edwards' Sapien 3 data
The shares of Edwards Lifesciences (EW) are rising after the company released data on its Sapien 3 transcathter aortic valve over the weekend. In notes to investors today, a number of analysts were upbeat on the data. BACKGROUND: Edwards yesterday announced that high- and intermediate-risk patients treated with Sapien 3 demonstrated lower mortality rates than patients treated with previous transcathter aortic valves, or TAVR, made by the company. The patients also had excellent clinical outcomes in the other primary endpoints of stroke and paravalvular regurgitation, the company stated. Meanwhile, a five year study of patients treated with the first generation SAPIEN device showed that the patients had equivalent outcomes to traditional open-heart surgery, and no structural valve deterioration requiring intervention, the company stated. ANALYST REACTION: Edwards' Sapien 3 data was impressive, as the device showed one of the lowest stroke and mortality rates of any major TAVR study so far, Bernstein analyst Derrick Sung wrote in a note to investors earlier today. Data presented by Edwards and other companies at the American College of Cardiology, or ACC, conference this weekend caused investors and the medical community to become more optimistic about the potential for TAVR devices to replace surgical valves, Sung stated. The analyst wrote that he continues to believe that investors are underestimating the potential size of the TAVR market. Also upbeat on Edwards' data was Wells Fargo, which wrote that the data exceeded high expectations and could pressure the FDA to approve Sapien 3 for intermediate risk patients earlier than Edwards' guidance of late 2016. WHAT'S NOTABLE: Analysts were also upbeat on data reported by other companies at the ACC conference. Medtronic's (MDT) data suggested that its CoreValve Evolut-R product may be as effective as Edwards' Sapien 3, Bernstein's Sung stated. The FDA appears to have allowed Boston Scientific's (BSX) left atrial appendage closure, Watchman, to be provided to more patients than expected, research firm Stifel believes. Meanwhile, St. Jude's (STJ) CardioMEMS device yielded "impressive" mortality data, the firm added. Stifel kept Buy ratings on both Medtronic and St. Jude. PRICE ACTION: In early afternoon trading, Edwards Lifesciences climbed 9% to $147.64, Boston Scientific advanced 4% to $17.27, St. Jude added 2% to $67.55, and Medtronic rose 1.3% to $77.50.
12:59 EDTDSWDSW March volatility increases into Q4 and outlook
Subscribe for More Information
10:44 EDTNFLXNetflix retreats after cut to sell on competition, cost concerns
The shares of Netflix (NFLX) are falling after research firm Evercore ISI downgraded the stock to Sell from Hold. Increased competition will force the company to increase its investments and the return from those investments is uncertain, the firm contends. WHAT'S NEW: In the U.S., technological advancements are enabling content providers to sell their programming to a wider range of Internet video distributors, Evercore ISI analyst Ken Sena wrote in a note to investors earlier today. Moreover, content providers themselves are now able to stream more of their programming online and obtain higher profits from doing so, Sena reported. The analyst noted that Apple (AAPL) recently obtained a three month exclusive deal to stream content form Time Warner's (TWX) HBO Now, while Yahoo (YHOO), Amazon (AMZN), and Hulu (DIS, CMCSA, NWSA) are all reportedly interested in obtaining streaming rights to "Seinfeld." Netflix's international expansion will not be sufficient to offset the increased competition, especially because foreign viewers are likely to watch less TV and be less interested in paying for TV content, the analyst believes. Furthermore, Netflix will face more competition from other Internet TV services overseas than in the U.S., according to Sena, who cut his 2015 consolidated operating income estimate for the company by 26% to $381M from $517M previously. In addition to cutting his rating, Sena lowered his price target on the shares to $380 from $450. PRICE ACTION: In early trading, Netflix sank $16, or 3.7%, to $422.
10:28 EDTNFLXOptions with increasing implied volatility
Options with increasing implied volatility: PVA NFLX BMRN DNOW MYL TEVA PEP GE
10:02 EDTNFLXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:37 EDTNFLXActive equity options trading on open
Subscribe for More Information
08:03 EDTWMBWilliams' Atlantic Sunrise pipeline to generate $1.6B economic impact
Subscribe for More Information
07:52 EDTNFLXNetflix downgraded at Evercore ISI
As previously reported, Evercore ISI downgraded Netflix to Sell from Hold. The firm downgraded shares and reduced its price target to $380 from $450 due to increasing competition among existing and emerging distributors combined with content providers who are becoming increasingly leveraged to new channels through OTT offerings of their own. Evercore ISI believes intensifying competition will necessitate increased investment with uncertain returns and lowered estimates.
07:30 EDTMDTAmerican College of Cardiology to hold an expo
Subscribe for More Information
07:22 EDTMDTMedtronic Edwards Lifesciences data 'impressive,' says Bernstein
Subscribe for More Information
06:16 EDTNFLXNetflix downgraded to Sell from Hold at Evercore ISI
March 15, 2015
15:27 EDTMDTMedtronic unveils data from high risk study of the CoreValve U.S. pivotal trial
Subscribe for More Information
15:23 EDTMDTMedtronic unveils preclinical outcomes of its novel Drug-Filled Stent
Subscribe for More Information
15:20 EDTMDTMedtronic announces outcomes for its next-generation CoreValve Evolut R System
Medtronic announced initial clinical outcomes for its next-generation CoreValve Evolut R System. At 30-days, the new recapturable, self-expanding valve showed no incidents of all-cause mortality or stroke in a high and extreme risk patient population. Data from the Evolut R Study, which enrolled 60 patients from six centers in the United Kingdom, Australia and New Zealand, were unveiled today at the 64th Annual Scientific Session of the American College of Cardiology. The CoreValve Evolut R System is not approved for commercial use in the United States where it is currently undergoing clinical trials. "Initial clinical experience with the Evolut R system is remarkable and ushers in a new era of TAVR technology that provides increased confidence with recapturability, excellent procedural results, and impressive clinical outcomes," said Ian Meredith, M.D., of Monash Heart - Monash Health, Melbourne, Australia, who is one of the investigators of the study. "The 14 French equivalent delivery system allowed transfemoral access for most patients and the recapturable technology enabled implanters to optimize valve placement for improved annular sealing and reduced conduction disturbances without compromise on mortality or stroke."
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use